Study design
This study was a 24-week prospective, 1:1 ratio randomized, single-blind clinical trial. It was registered in the Iranian Registry of Clinical Trials (IRCT): IRCT20190122042450N3. The study protocol was approved by the Ethics Committee (EC) of the Institutional Review Board (IRB) of the Iran University of Medical Science; ethical code: IR.IUMS.REC.1398.1408. Iran University of Medical Science (IUMS) funded the study. All of the participants signed a written informed consent before enrollment and after a face-to-face discussion about the study procedures and outcomes. Abidi pharmaceutical company supplied the medication. However, they had no role in data management, analyses, and writing final report.